ALX Oncology (NASDAQ:ALXO) Shares Up 3% – Here’s What Happened

Posted by George Bondi on Oct 2nd, 2026

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) rose 3% during trading on Wednesday. The company traded as high as $1.46 and last traded at $1.39. 1,343,748 shares were traded during mid-day trading, an increase of 22% from the average session volume of 1,099,515 shares. The stock had previously closed at $1.35.

Analyst Ratings Changes

Separately, Weiss Ratings raised ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.60.

Read Our Latest Research Report on ALX Oncology

ALX Oncology Stock Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 9.71 and a quick ratio of 9.71. The stock has a market capitalization of $170.78 million, a price-to-earnings ratio of -1.10 and a beta of 0.47. The stock has a 50-day moving average of $1.87 and a 200 day moving average of $1.88.

ALX Oncology (NASDAQ:ALXO – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. On average, analysts expect that ALX Oncology Holdings Inc. will post -0.59 EPS for the current year.

Hedge Funds Weigh In On ALX Oncology

Several institutional investors have recently modified their holdings of the stock. Beacon Pointe Advisors LLC acquired a new position in ALX Oncology during the second quarter valued at approximately $26,000. Callan Family Office LLC acquired a new stake in shares of ALX Oncology in the 2nd quarter valued at about $46,000. The Manufacturers Life Insurance Company acquired a new stake in ALX Oncology in the 2nd quarter valued at approximately $64,000. AXQ Capital LP acquired a new stake in shares of ALX Oncology in the second quarter valued at approximately $84,000. Finally, Squarepoint Ops LLC bought a new stake in ALX Oncology during the 2nd quarter worth about $97,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Company Profile

(Get Free Report)

ALX Oncology Holdings Inc is a clinical-stage biotechnology company focused on developing therapies that activate the immune system to fight cancer. The company’s approach targets the CD47-SIRPα pathway, an innate immune checkpoint that cancer cells can use to avoid being identified and destroyed by macrophages and other immune cells.

ALX Oncology’s lead product candidate is evorpacept, formerly known as ALX148. Evorpacept is an investigational fusion protein designed to block the CD47 “don’t eat me” signal while limiting the binding of normal blood cells.